Delivery Order SPE2DB22D3501-SPE2DB25FWP23
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Janumet 50-1,000 mg tablets (180-count units) valued at $4,159.32. This is a firm fixed-price delivery order with no set-aside designation, indicating the award was made through open competition. The contract represents a single delivery transaction under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 10, 2025, for the supply of Janumet 50-1,000 mg tablets (180-count units) with a ceiling value of $3,078.36. This firm fixed-price delivery order, which is not set aside for any specific business category, represents a competitively awarded transaction under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical. The performance location is identified as...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 16, 2025, for the supply of Janumet 50-1,000 mg tablets (180-count units) under a firm fixed-price contract with a ceiling value of $4,174.60. This non-set-aside competitive award is a child delivery order issued against AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The place of...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of 180 tablets of Janumet 50-1,000 mg, a combination medication used in diabetes management. This firm fixed-price delivery order, valued at $19,727.92, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion pharmaceutical supply vehicle running through December 2026. The award was...
- The Defense Logistics Agency awarded a competitive delivery order to AmerisourceBergen Drug Corp for the supply of Janumet 50-1,000 mg tablets (180-count units) with a ceiling value of $4,620.99 and a firm fixed price structure. The order was issued on September 10, 2025, with an ultimate completion date of September 11, 2025. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX,...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,610.07 to AmerisourceBergen Drug Corp on July 16, 2025, for the supply of Janumet 50-1,000 mg tablets (180-count units). This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of July 17, 2025. The pharmaceutical products will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency (DLA) awarded a delivery order contract to AmerisourceBergen Drug Corp, the major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, on September 8, 2025, for the supply of Janumet 50-1,000 mg tablets (180-count units) with a ceiling value of $3,223.51. This competitively awarded, firm fixed-price delivery order carries an ultimate completion date of September 9, 2025, and is being performed at the contractor's Conshohocken facility. No set-aside...
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Janumet 50-1,000 mg tablets in quantities of 1,000 units, with a ceiling value of $2,012.06. This is a firm fixed price delivery order with an ultimate completion date of August 12, 2025, and represents a non-set-aside competitive award. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Janumet 50-1,000 mg tablets (180 count) with a contract ceiling value of $4,393.68. This is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The order is scheduled for ultimate completion on July 23, 2025, and will be fulfilled from the vendor's location in Conshohocken, Pennsylvania. This delivery order represents a...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Janumet 50-1,000 mg tablets (180-count units) with a ceiling value of $5,460.68. This firm fixed-price delivery order is part of AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (designated SPE2DX), valued at $999,999,999.00 and extending through December 2026. The contract was competitively awarded with no set-aside designation,...
- SPE2DB22D3501Indefinite Delivery Contract
- SPE2DB22D3501-SPE2DB25FWP23Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Janumet 50-1,000 mg tablets (180 count) with a ceiling value of $14,237.99. This is a firm fixed-price delivery order with no set-aside designation, indicating competitive award status. The contract represents a single delivery order placed under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion global pharmaceutical support vehicle running through December 2026 that enables the company to supply a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs worldwide. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical procurement, particularly supporting military and veteran healthcare systems through the Defense Logistics Agency. The company's contract awards demonstrate capability in fulfilling diverse pharmaceutical needs, including diabetes medications, neurological treatments, antibiotics, and specialized medical supplies across multiple therapeutic domains. This delivery order for Janumet—an oral combination medication for type 2 diabetes management—reflects the company's ongoing role as a primary vendor within the DLA's medical supply chain supporting the Defense Health Agency and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $14.2k | 7/24/25 |